Haller, Heidemarie ORCID: 0000-0001-7973-4071, Choi, Kyung-Eun, Lange, Silke, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Paul, Anna, Cramer, Holger ORCID: 0000-0002-3640-8046, Dobos, Gustav and Voiss, Petra ORCID: 0000-0002-9005-0479 (2021). Effects of an Integrative Mind-Body-Medicine Group Program on Breast Cancer Patients During Chemotherapy: An Observational Study. Curr. Pharm. Design, 27 (8). S. 1112 - 1121. SHARJAH: BENTHAM SCIENCE PUBL LTD. ISSN 1873-4286

Full text not available from this repository.


Background: Breast cancer is one of the leading cancers in women in the Western world. Cancer treatment, especially chemotherapy, is often associated with physical and psychosocial side effects. Objective: To improve the quality of life and manage side effects, a new integrative mind-body-medicine group concept for breast cancer patients receiving chemotherapy was developed and pilot tested. Methods: Breast cancer patients participated in a 66 hours mind-body-medicine group program tailored to the needs of cancer patients during chemotherapy. The program was integrated into standard care encompassing mindfulness training, yoga, moderate exercise, nutrition, complementary self-help strategies, cognitive restructuring, and acupuncture. Quality of life (EORTC QLQ-C30), depression and anxiety (HADS), stress (PSS-10), and fatigue (BFI) were assessed before and after the program, as well as satisfaction and safety. Analyses were carried out on exploratory basis with paired samples t-tests. Results: Fifty-seven female patients, aged 51.3 +/- 10.5 years, with breast cancer diagnoses were enrolled. After completing the program, global EORTC quality of life was improved (D=9.5; 95%-CI=[2.9|16.1]; p=.005), although the EORTC-symptom scales assessing fatigue (D=9.9; 95%-CI=[1|18.8]; p=.030), nausea (D=7.1; 95%CI=[0.6|13.6]; p=.031), and dyspnea (D=12.5; 95%-CI=[2.9|22.1]; p=.011) were found to be increased. Stress (D=-3.5; 95%-CI=[-5|-2.1]; p=.000), anxiety (D=- 3.8; 95%-CI=[-4.9|-2.7]; p=.000) and depression (D=-3.9; 95%-CI=[-4.9|-2.8]; p=.000) were also found to be significantly reduced. Regarding the severity of (D=0.2; 95%- CI=[-0.8|0.5]; p=.644) and the impairment due to fatigue (D=0.1; 95%-CI=[-0.8|0.6]; p=.696), no significant worsening was observed. Patients were satisfied with the program. No serious adverse events were reported. Conclusion: Breast cancer patients benefit from an integrative mind-body-medicine group program during chemotherapy regarding the quality of life and psychological symptoms. Randomized controlled trials are warranted.

Item Type: Journal Article
CreatorsEmailORCIDORCID Put Code
Haller, HeidemarieUNSPECIFIEDorcid.org/0000-0001-7973-4071UNSPECIFIED
Kuemmel, SherkoUNSPECIFIEDorcid.org/0000-0001-9355-494XUNSPECIFIED
Cramer, HolgerUNSPECIFIEDorcid.org/0000-0002-3640-8046UNSPECIFIED
Voiss, PetraUNSPECIFIEDorcid.org/0000-0002-9005-0479UNSPECIFIED
URN: urn:nbn:de:hbz:38-576764
DOI: 10.2174/1381612826666201211111122
Journal or Publication Title: Curr. Pharm. Design
Volume: 27
Number: 8
Page Range: S. 1112 - 1121
Date: 2021
Place of Publication: SHARJAH
ISSN: 1873-4286
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
Pharmacology & PharmacyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/57676


Downloads per month over past year



Actions (login required)

View Item View Item